ONCT vs. NKGN, PTN, LIPO, BCLI, FRTX, GTBP, GNPX, ALBT, NLSP, and SNGX
Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include NKGen Biotech (NKGN), Palatin Technologies (PTN), Lipella Pharmaceuticals (LIPO), Brainstorm Cell Therapeutics (BCLI), Fresh Tracks Therapeutics (FRTX), GT Biopharma (GTBP), Genprex (GNPX), Avalon GloboCare (ALBT), NLS Pharmaceutics (NLSP), and Soligenix (SNGX). These companies are all part of the "pharmaceutical products" industry.
Oncternal Therapeutics vs.
Oncternal Therapeutics (NASDAQ:ONCT) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.
Oncternal Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 1,798.97%. Given Oncternal Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Oncternal Therapeutics is more favorable than NKGen Biotech.
Oncternal Therapeutics received 32 more outperform votes than NKGen Biotech when rated by MarketBeat users.
Oncternal Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
NKGen Biotech has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. NKGen Biotech's return on equity of 0.00% beat Oncternal Therapeutics' return on equity.
Oncternal Therapeutics has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oncternal Therapeutics had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Oncternal Therapeutics and 0 mentions for NKGen Biotech. Oncternal Therapeutics' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.
16.0% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Oncternal Therapeutics beats NKGen Biotech on 10 of the 16 factors compared between the two stocks.
Get Oncternal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncternal Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ONCT) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy ONCT Stock Free ONCT Stock Alerts